{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:16:21Z","timestamp":1769768181552,"version":"3.49.0"},"reference-count":37,"publisher":"Akademiai Kiado Zrt.","issue":"14","license":[{"start":{"date-parts":[[2023,4,9]],"date-time":"2023-04-09T00:00:00Z","timestamp":1680998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,4,9]]},"abstract":"<jats:p>A kevert nagysejtes neuroendokrin carcinoma ritka, nem kissejtes morfol\u00f3gi\u00e1j\u00fa\n                    t\u00fcd\u0151r\u00e1k, melynek kezel\u00e9s\u00e9re kev\u00e9s kutat\u00e1s f\u00f3kusz\u00e1l. Ezen esetek patogenezis\u00e9ben\n                    az anaplasticus lymphoma kin\u00e1z <jats:italic>(ALK)<\/jats:italic> f\u00fazi\u00f3s g\u00e9n szerepe\n                    ritkas\u00e1g, ugyanakkor a mut\u00e1ci\u00f3 jelenl\u00e9te eset\u00e9n az\n                    <jats:italic>ALK<\/jats:italic>-inhibitorok \u00edg\u00e9retes ter\u00e1pi\u00e1s lehet\u0151s\u00e9get jelentenek a\n                    citosztatikumok helyett. Az 52 \u00e9ves, t\u00fcnetmentes n\u0151n\u00e9l rutin\n                    mellkasr\u00f6ntgenvizsg\u00e1lat sor\u00e1n t\u00e9rfoglal\u00f3 folyamat mer\u00fclt fel, melyet a mellkasi\n                    komputertomogr\u00e1fi\u00e1s vizsg\u00e1lat meger\u0151s\u00edtett. A tumort lobectomia r\u00e9v\u00e9n\n                    elt\u00e1vol\u00edtott\u00e1k. A sz\u00f6vettani vizsg\u00e1lat papillaris predomin\u00e1ns t\u00fcd\u0151\n                    adenocarcinom\u00e1t igazolt, melyet posztoperat\u00edv kemoter\u00e1pia \u00e9s besug\u00e1rz\u00e1s\n                    k\u00f6vetett. 3 \u00e9vvel k\u00e9s\u0151bb k\u00f6zponti idegrendszeri t\u00fcnetek miatt koponya k\u00e9palkot\u00f3\n                    vizsg\u00e1lat t\u00f6rt\u00e9nt, melynek sor\u00e1n \u00e1tt\u00e9t igazol\u00f3dott. Az agyi metaszt\u00e1zisok\n                    elt\u00e1vol\u00edt\u00e1sra ker\u00fcltek. A sz\u00f6vettani vizsg\u00e1lat nagysejtes neuroendokrin\n                    carcinoma \u00e1tt\u00e9t\u00e9t igazolta. Az \u00e1tt\u00e9t \u00e9s a kimetszett t\u00fcd\u0151r\u00e9szlet metszeteinek\n                    \u00fajb\u00f3li elemz\u00e9se, illetve a molekul\u00e1ris vizsg\u00e1lat alapj\u00e1n\n                    <jats:italic>ALK<\/jats:italic>-transzlok\u00e1lt, kevert, nagysejtes neuroendokrin carcinom\u00e1t\n                    k\u00f3rism\u00e9zt\u00fcnk. Alectinib (Alecensa)-kezel\u00e9s indult, melynek hat\u00e1s\u00e1ra az id\u0151k\u00f6zben\n                    megjelent m\u00e1j\u00e1tt\u00e9tek regresszi\u00f3t mutattak. A kontroll radiol\u00f3giai vizsg\u00e1latok a\n                    kezel\u00e9s kezdete \u00f3ta eltelt 3 \u00e9vben progresszi\u00f3t nem igazoltak. Az\n                        <jats:italic>ALK<\/jats:italic>-transzlok\u00e1ci\u00f3 kimutat\u00e1sa, illetve az\n                        <jats:italic>ALK<\/jats:italic>-inhibitorok alkalmaz\u00e1s\u00e1nak kutat\u00e1sa els\u0151sorban a t\u00fcd\u0151\n                    adenocarcinom\u00e1kra helyezi a hangs\u00falyt. Esetismertet\u00e9s\u00fcnkkel arra szeretn\u00e9nk\n                    felh\u00edvni a figyelmet, hogy a kevert, adenocarcinoma-komponenst is tartalmaz\u00f3,\n                    neuroendokrin tumorok eset\u00e9n is \u00e9rdemes a \u2019driver\u2019 mut\u00e1ci\u00f3k vizsg\u00e1lata, mivel a\n                    c\u00e9lzott kezel\u00e9s eredm\u00e9nyes alternat\u00edv\u00e1t jelenthet. Orv Hetil. 2023; 164(14):\n                    548\u2013554.<\/jats:p>","DOI":"10.1556\/650.2023.32738","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T14:03:10Z","timestamp":1681135390000},"page":"548-554","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Az alectinib \u00e9s a t\u00fcd\u0151 kevert nagysejtes neuroendokrin carcinom\u00e1ja."],"prefix":"10.1556","volume":"164","author":[{"given":"Fanni","family":"Heged\u0171s","sequence":"first","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathologiai Int\u00e9zet Szeged, \u00c1llom\u00e1s utca 2., 6725 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farkas","family":"S\u00fck\u00f6sd","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathologiai Int\u00e9zet Szeged, \u00c1llom\u00e1s utca 2., 6725 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Tiszlavicz","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathologiai Int\u00e9zet Szeged, \u00c1llom\u00e1s utca 2., 6725 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"Fur\u00e1k","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Seb\u00e9szeti Klinika Szeged Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"P\u00e1lf\u00f6ldi","sequence":"additional","affiliation":[{"name":"Csongr\u00e1d-Csan\u00e1d Megyei Mellkasi Betegs\u00e9gek Szakk\u00f3rh\u00e1za Deszk Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Fejes","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Radiol\u00f3giai Klinika Szeged Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Zombori","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathologiai Int\u00e9zet Szeged, \u00c1llom\u00e1s utca 2., 6725 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424. Erratum: CA Cancer J Clin. 2020; 70: 313.","DOI":"10.3322\/caac.21492"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.path.2019.08.012","article-title":"Neuroendocrine tumors of the lung: updates and diagnostic pitfalls","volume":"12","author":"2 Hung","year":"2019","unstructured":"2 Hung YP. Neuroendocrine tumors of the lung: updates and diagnostic pitfalls. Surg Pathol Clin. 2019; 12: 1055-1071.","journal-title":"Surg Pathol Clin"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3 Fur\u00e1k J, Szab\u00f3 Z, Horv\u00e1th T, et al. Non-intubated, uniportal, video assisted thoracic surgery [VATS] lobectomy, as a new procedure in our department. [Nem intub\u00e1lt, spont\u00e1n l\u00e9gz\u0151 betegn\u00e9l egy metsz\u00e9sb\u0151l, minim\u00e1lisan invaz\u00edv m\u00f3don elv\u00e9gzett t\u00fcd\u0151lebeny-elt\u00e1vol\u00edt\u00e1s mint \u00faj m\u0171t\u00e9ti elj\u00e1r\u00e1s klinik\u00e1nk gyakorlat\u00e1ban.] Magy Seb. 2017; 70: 113-117. [Hungarian]","DOI":"10.1556\/1046.70.2017.2.1"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: Precision medicine takes on drug resistance","volume":"7","author":"4 Lin","year":"2017","unstructured":"4 Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision medicine takes on drug resistance. Cancer Discov. 2017; 7: 137-155.","journal-title":"Cancer Discov"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1242\/jcs.01183","article-title":"ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth","volume":"117","author":"5 Motegi","year":"2004","unstructured":"5 Motegi A, Fujimoto J, Kotani M, et al. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci. 2004; 117: 3319-3329.","journal-title":"J Cell Sci"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 Elliott J, Bai Z, Hsieh SC, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PLOS ONE 2020; 15: e0229179.","DOI":"10.1371\/journal.pone.0229179"},{"key":"ref6","unstructured":"7 WHO Classification of Tumours, Editorial Board. Thoracic tumours. International Agency for Research on Cancer, Lyon, 2021 April 15. (WHO classification of tumours series, 5th ed.; Vol. 5.)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ijc.33853","article-title":"In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma","volume":"150","author":"8 Hermans","year":"2022","unstructured":"8 Hermans BC, Derks JL, Hillen LM, et al. In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma. Int J Cancer 2022; 150: 802-815.","journal-title":"Int J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Zombori T, Juh\u00e1sz-Nagy G, Tiszlavicz L, et al. Large-cell neuroendocrine carcinoma of the lung - challenges of diagnosis and treatment. [Nagysejtes neuroendocrin carcinoma - a k\u00f3risme \u00e9s a kezel\u00e9s neh\u00e9zs\u00e9gei.] Orv Hetil. 2020; 161: 313-319. [Hungarian]","DOI":"10.1556\/650.2020.31581"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","article-title":"Targeted therapy and checkpoint immunotherapy in lung cancer","volume":"13","author":"Ruiz-Cordero R","year":"2020","unstructured":"10 Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020; 13: 17-33.","journal-title":"Surg Pathol Clin"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.2147\/OTT.S172124","article-title":"ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature","volume":"11","author":"11 Zheng","year":"2018","unstructured":"11 Zheng Q, Zheng M, Jin Y, et al. ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature. Onco Targets Ther. 2018; 11: 4991-4998.","journal-title":"Onco Targets Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"12 Du","year":"2018","unstructured":"12 Du X, Shao Y, Qin HF, et al. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer 2018; 9: 423-430.","journal-title":"Thorac Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1200\/PO.20.00348","article-title":"Metastatic large-cell neuroendocrine lung carcinoma with ALK fusion oncogene with partial response to alectinib","volume":"5","author":"13 Leblanc","year":"2021","unstructured":"13 Leblanc A, Owen S, Fiset PO, et al. Metastatic large-cell neuroendocrine lung carcinoma with ALK fusion oncogene with partial response to alectinib. JCO Precis Oncol. 2021; 5: 802-807.","journal-title":"JCO Precis Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.21873\/anticanres.13127","article-title":"Use of ALK immunohistochemistry for optimal therapeutic strategy of pulmonary large-cell neuroendocrine carcinoma and identification of a novel KIF5B-ALK fusion oncokinase","volume":"39","author":"14 Shimizu","year":"2019","unstructured":"14 Shimizu N, Akashi Y, Fujii T, et al. Use of ALK immunohistochemistry for optimal therapeutic strategy of pulmonary large-cell neuroendocrine carcinoma and identification of a novel KIF5B-ALK fusion oncokinase. Anticancer Res. 2019; 39: 413-420.","journal-title":"Anticancer Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/curroncol29020072","article-title":"A case of ALK-rearranged combined lung adenocarcinoma and neuroendocrine carcinoma with diffuse bone metastasis and partial response to alectinib","volume":"29","author":"15 Lim","year":"2022","unstructured":"15 Lim CA, Banyi N, Tucker T, et al. A case of ALK-rearranged combined lung adenocarcinoma and neuroendocrine carcinoma with diffuse bone metastasis and partial response to alectinib. Curr Oncol. 2022; 29: 848-852.","journal-title":"Curr Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.lungcan.2020.06.005","article-title":"ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: clinical and molecular description of two cases","volume":"146","author":"16 Fares","year":"2020","unstructured":"16 Fares AF, Lok BH, Zhang T, et al. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: clinical and molecular description of two cases. Lung Cancer 2020; 146: 350-354.","journal-title":"Lung Cancer"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Masuda K, Saiki M, Shimamura S, et al. Dramatic response to alectinib in an ALK-positive LCNEC patient with a poor performance status: a case report. Respirol Case Rep. 2021; 9: e0817.","DOI":"10.1002\/rcr2.817"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18 Omachi N, Shimizu S, Kawaguchi T, et al. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib. J Thorac Oncol. 2014; 9: e40-e42.","DOI":"10.1097\/JTO.0000000000000103"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19 Wang S, Wu X, Zhao J, et al. Next-generation sequencing identified a novel crizotinib-sensitive PLB1-ALK rearrangement in lung large-cell neuroendocrine carcinoma. Clin Lung Cancer 2021; 22: e366-e370.","DOI":"10.1016\/j.cllc.2020.05.026"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2169\/internalmedicine.9368-17","article-title":"Large cell neuroendocrine carcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement with response to alectinib","volume":"57","author":"20 Hayashi","year":"2018","unstructured":"20 Hayashi N, Fujita A, Saikai T, et al. Large cell neuroendocrine carcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement with response to alectinib. Intern Med. 2018; 57: 713-716.","journal-title":"Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/pcmedi\/pbz005","article-title":"A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance","volume":"2","author":"21 Wang","year":"2019","unstructured":"21 Wang Y, Tian P, Wang W, et al. A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance. Precis Clin Med. 2019; 2: 1-5.","journal-title":"Precis Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/his.13388","article-title":"Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors","volume":"72","author":"22 Hoton","year":"2018","unstructured":"22 Hoton D, Humblet Y, Libbrecht L. Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors. Histopathology 2018; 72: 707-710.","journal-title":"Histopathology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"823813","DOI":"10.3389\/fonc.2022.823813","article-title":"Case report: a pregnant woman diagnosed as ALK-rearrangement lung large cell neuroendocrine cancer with brain metastasis","volume":"12","author":"23 Fu","year":"2022","unstructured":"23 Fu Z, Zhu G, Wang L, et al. Case report: a pregnant woman diagnosed as ALK-rearrangement lung large cell neuroendocrine cancer with brain metastasis. Front Oncol. 2022; 12: 823813.","journal-title":"Front Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"9705","DOI":"10.3390\/ijms21249705","article-title":"Heterogeneous tumor-immune microenvironments between primary and metastatic tumors in a patient with ALK rearrangement-positive large cell neuroendocrine carcinoma","volume":"21","author":"24 Tashiro","year":"2020","unstructured":"24 Tashiro T, Imamura K, Tomita Y, et al. Heterogeneous tumor-immune microenvironments between primary and metastatic tumors in a patient with ALK rearrangement-positive large cell neuroendocrine carcinoma. Int J Mol Sci. 2020; 21: 9705.","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25 Li Y, Pan Y, Wang R, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLOS ONE 2013; 8: e69016.","DOI":"10.1371\/journal.pone.0069016"},{"key":"ref25","unstructured":"26 T\u00edm\u00e1r J, Lotz G, R\u00e1s\u00f3 E, et al. Molecular diagnostics of ALK-positive lung cancer. [Az ALK-pozit\u00edv t\u00fcd\u0151r\u00e1k korszer\u0171 diagnosztik\u00e1ja.] Magy Onkol. 2017; 61: 301-311. [Hungarian]"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"27 Solomon","year":"2018","unstructured":"27 Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018; 36: 2251-2258.","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s40265-013-0142-z","article-title":"Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer","volume":"73","author":"28 Frampton","year":"2013","unstructured":"28 Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013; 73: 2031-2051.","journal-title":"Drugs"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29 Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials. Curr Oncol. 2018; 25(Suppl 1): S59-S67.","DOI":"10.3747\/co.25.3760"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14728214.2018.1527902","article-title":"Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors","volume":"23","author":"30 Spagnuolo","year":"2018","unstructured":"30 Spagnuolo A, Maione P, Gridelli C. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opin Emerg Drugs 2018; 23: 231-241.","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"31 Shaw","year":"2020","unstructured":"31 Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020; 383: 2018-2029.","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"32 Peters","year":"2017","unstructured":"32 Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017; 377: 829-838.","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33 Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021","DOI":"10.1016\/j.jtho.2021.07.035"},{"key":"ref33","unstructured":"16: 2091-2108. Erratum: J Thorac Oncol. 2022 Oct 14. S1556-0864(22)00349-5. . [Online ahead of print] PMID: 36244926."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"34 Horn","year":"2021","unstructured":"34 Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021; 7: 1617-1625.","journal-title":"JAMA Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/14737140.2021.1940964","article-title":"The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance","volume":"21","author":"35 Haratake","year":"2021","unstructured":"35 Haratake N, Toyokawa G, Seto T, et al. The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance. Expert Rev Anticancer Ther. 2021; 21: 975-988.","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"36 Baine MK, Sinard JH, Cai G, et al. A semiquantitative scoring system may allow biopsy diagnosis of pulmonary large cell neuroendocrine carcinoma. Am J Clin Pathol. 2020; 153: 165-174. Erratum: Am J Clin Pathol. 2020; 153: 286.","DOI":"10.1093\/ajcp\/aqz149"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/14\/article-p548.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/14\/article-p548.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/14\/article-p548.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T14:37:59Z","timestamp":1698244679000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/14\/article-p548.xml"}},"subtitle":["Egy sikeres eset bemutat\u00e1sa"],"short-title":[],"issued":{"date-parts":[[2023,4,9]]},"references-count":37,"journal-issue":{"issue":"14"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32738","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,9]]}}}